Risk adapted therapy for multiple myeloma: Back to basics

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2219-2220

  Kumar, Shaji K ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; COMORBIDITY; DRUG EFFICACY; HUMAN; MULTIPLE MYELOMA; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; COMPLICATION; FEMALE; HEART FAILURE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEART FAILURE; HUMANS; MALE; MULTIPLE MYELOMA;

EID: 84925326082     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.905775     Document Type: Note

References (12)

1. Kumar S. Multiple myeloma - current issues and controversies. Cancer Treat Rev 2010;36(Suppl. 2):S3-S11.
2. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013;88:360-376.
3. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2013 Oct 25. [Epub ahead of print]
4. Zhou F, Ling C, Guo L, et al. Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. Leuk Lymphoma 2014;55:2271-2276.
5. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-2972.
6. Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010;85:232-238.
7. Honton B, Despas F, Dumonteil N, et al. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol 2014;28:349-352.
8. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98:1753-1761.
9. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519-4529.
10. Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005;80:1578-1582.
11. Zhou F, Guo L, Shi H, et al. Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10:51-55.
12. de Weerdt O, van de Donk NW, Veth G, et al. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001;59:50-56.